

DRUG NAME: Durvalumab

SYNONYM(S): MEDI 4736¹

COMMON TRADE NAME(S): IMFINZI®

CLASSIFICATION: immunotherapy

Special pediatric considerations are noted when applicable, otherwise adult provisions apply.

MECHANISM OF ACTION:

Durvalumab is a fully human immunoglobulin G1 kappa monoclonal antibody checkpoint inhibitor that blocks the interaction between programmed death ligand 1 (PD-L1) and programmed death 1 (PD-1) and CD80 on T-cells. PD-L1 blockade enhances antitumour immune responses and leads to increased T-cell activation and delayed tumour growth.^{2,3}

PHARMACOKINETICS:

Distribution	steady state at 16 weeks	
	cross blood brain barrier?	no information found
	volume of distribution	5.6 L
	plasma protein binding	no information found
Metabolism	not defined; expected to be degraded into small peptides and amino acids via catabolic pathways (similar to endogenous IgG antibodies)	
	active metabolite(s)	no information found
	inactive metabolite(s)	no information found
Excretion	clearance decreases over time (not considered clinically relevant)	
	urine	no information found
	feces	no information found
	terminal half life	17 days
	clearance	8.2 mL/h

Adapted from standard reference² unless specified otherwise.

USES:

Primary uses:

- *Bladder cancer
- *Lung cancer, non-small cell
- *Health Canada approved indication

Other uses:

SPECIAL PRECAUTIONS:

Caution:

- avoid systemic **corticosteroids** or **immunosuppressants** prior to starting durvalumab due to potential interference with the efficacy of durvalumab; corticosteroids or immunosuppressants may be used *during* treatment with durvalumab for the management of immune-mediated adverse reactions^{2,4}

Carcinogenicity: no information found

Mutagenicity: no information found

Fertility: In animal studies, no notable effects on male or female reproductive organs were reported.²

Pregnancy: Durvalumab has not been studied in pregnant women. Endogenous IgG1 is known to cross the placental barrier, particularly during the third trimester. Therefore, as a humanized IgG1 antibody, durvalumab is expected to be transmitted from mother to fetus. In animal models, blocking PD-L1 signalling disrupted tolerance to the fetus and resulted in increased rates of abortion and stillbirth. Women of reproductive potential should use effective contraception while on durvalumab and for three months after treatment has been discontinued.²

Breastfeeding is not recommended due to the potential secretion into human breast milk. In animal studies, durvalumab was detected in breast milk and was associated with premature neonatal death. Women should wait at least three months after the last dose of durvalumab before breastfeeding.²

SIDE EFFECTS:

The table includes adverse events that presented during drug treatment but may not necessarily have a causal relationship with the drug. Because clinical trials are conducted under very specific conditions, the adverse event rates observed may not reflect the rates observed in clinical practice. Adverse events are generally included if they were reported in more than 1% of patients in the product monograph or pivotal trials, and/or determined to be clinically important.^{5,6}

ORGAN SITE	SIDE EFFECT
Clinically important side effects are in bold, italics	
blood and lymphatic system/ febrile neutropenia	anemia (8-47%, severe 3-12%)
	lymphocytopenia (43-45%, severe 11%) ^{2,3}
	neutropenia (8%, severe 1%)
endocrine	hyperthyroidism (5-8%)
	hypothyroidism (7-12%, severe <1%)
gastrointestinal	<i>emetogenic potential: low</i> ^{6,7}
	abdominal pain (10-14%, severe <1%) ^{2,3}
	colitis (\leq 18%) ³
	constipation (12-26%, severe \leq 2%)
	diarrhea (17-18%, severe <1%)
	nausea (14-22%, severe 2%)
	vomiting (8-13%, severe \leq 2%)
general disorders and administration site conditions	<i>extravasation hazard: none</i> ⁸
	edema, peripheral (8-15%, severe 2%) ^{2,3}
	fatigue, asthenia (11-39%, severe \leq 3%) ^{2,3}
	infusion related reaction (1-2%, severe <1%); see paragraph following Side Effects table
	pyrexia (15-16%, severe <1%)
hepatobiliary	hepatitis (12%) ³ ; sometimes fatal
immune system (see paragraph following	adrenal insufficiency (<1%; severe <1%); median onset 141 days
	aseptic meningitis (<1%, severe <1%)

ORGAN SITE	SIDE EFFECT
Clinically important side effects are in bold, italics	
Side Effects table)	colitis ($\leq 2\%$, severe $< 1\%$); median onset 74 days
	diabetes mellitus, type I ($< 1\%$; severe $< 1\%$); median onset 42 days
	diarrhea (1-2%, severe $< 1\%$); median onset 74 days
	hemolytic anemia ($< 1\%$) ³
	hepatitis ($\leq 2\%$, severe $\leq 2\%$); median onset 70 days; has been fatal
	hyperthyroidism (1-3%); median onset 41 days
	hypophysitis/hypopituitarism ($< 1\%$; severe $< 1\%$)
	hypothyroidism (5-9%, severe $< 1\%$); median onset 85-107 days
	keratitis, uveitis ($< 1\%$) ^{2,3}
	myocarditis ($< 1\%$, severe $< 1\%$)
	myositis, polymyositis ($< 1\%$, severe $< 1\%$): has been fatal
	nephritis ($\leq 6\%$, severe $< 1\%$) ^{2,3} ; median onset 95 days
	pancreatitis ($< 1\%$) ⁹
	pneumonitis ($\leq 11\%$, severe $\leq 3\%$); median onset 53 days
	rash (1-2%, severe $< 1\%$); median onset 36-74 days
thrombocytopenic purpura ($< 1\%$, severe $< 1\%$); has been fatal	
infections and infestations (see paragraph following Side Effects table)	dental, oral soft tissue infection (4%)
	influenza (3%)
	pneumonia (17%, severe 7%); sometimes fatal
	sepsis (3%, severe 3%)
	thrush (3%)
	upper respiratory tract infections (26%, severe $< 1\%$)
urinary tract infection (6-16%, severe 4%)	
investigations	alkaline phosphatase increase (28%, severe 4%)
	ALT increase (8-39%, severe 1-2%)
	AST increase (8-36%, severe 2-4%)
	bilirubin increase (11%, severe 1-2%) ^{2,3}
	creatinine increase (5-33%, severe $\leq 2\%$)
	gamma-glutamyltransferase increase (2-24%, severe 1%) ^{2,3}
	thyroid stimulating hormone decrease (32%)
	thyroid stimulating hormone increase (27%)
metabolism and nutrition	appetite decrease (14-23%, severe $< 1\%$)
	dehydration ($\geq 3\%$, severe $\geq 3\%$) ³
	hypercalcemia (15%, severe 3%)
	hyperglycemia (44-52%, severe 3%) ^{2,3}

ORGAN SITE	SIDE EFFECT
Clinically important side effects are in bold, italics	
	hyperkalemia (18-32%, severe 2%) ^{2,3}
	hypermagnesemia (11%, severe 4%)
	hypoalbuminemia (37%, severe 1%)
	hypocalcemia (46%) ³
	hypokalemia (10%, severe 1%)
	hyponatremia (33-45%, severe 6-11%) ^{2,3}
musculoskeletal and connective tissue	arthralgia (11-12%, severe <1%)
	back pain (11-17%, severe ≤4%)
	musculoskeletal pain (24%) ³
	myalgia (8%, severe <1%)
renal and urinary	acute kidney injury (5%, severe 5%)
	dysuria (2%)
respiratory, thoracic and mediastinal	cough (12-40%, severe <1%)
	dysphonia (4%)
	dyspnea (12-22%, severe 2%)
	pneumonitis (1-34%, severe ≤5%); sometimes fatal
skin and subcutaneous tissue	night sweats (2%)
	pruritus (6-12%)
	rash (14-26%, severe <1%) ^{2,3}

Adapted from standard reference² unless specified otherwise.

Immune-mediated adverse events are a spectrum of side effects caused by general immunologic enhancement that can occur at any time during durvalumab treatment or months after discontinuation. Consider the etiology of reported endocrinopathy, diarrhea/colitis, hepatitis, ocular toxicity, pneumonitis, rash, etc. to be immune-mediated until another etiology is confirmed. Early identification and timely intervention are important as symptoms can be severe or fatal if not recognized and treated quickly. Strongly advise patients to promptly report symptoms and to avoid self-treatment without medical advice. Management of symptoms is based on the severity of the reaction and may require treatment interruption, administration of corticosteroids, and/or supportive care. For severe symptoms, if there is no improvement within 72 hours despite steroids, consider initiating additional immunosuppressive therapy. Corticosteroids should be appropriately tapered following resolution of symptoms to grade 1 or less (grade zero for myocarditis). Durvalumab may be restarted once the steroid dose has been reduced to 10 mg/day or less of prednisone (or equivalent) and symptoms remain controlled. Referral to appropriate medical specialty may be required to manage immune-mediated complications related to treatment. Most immune-mediated endocrinopathies can be managed by withholding durvalumab until the patient is clinically stable and/or initiating symptomatic management as indicated (e.g., insulin, thyroid hormone replacement, etc.). Antibiotic, antifungal, and antiviral prophylaxis can be considered for patients on long term corticosteroid treatment (e.g., oral trimethoprim/sulfamethoxazole for the prevention of *Pneumocystis jiroveci* pneumonia). **Permanent discontinuation** of durvalumab should be considered for the following:

- grade 3-4: pneumonitis, hepatitis, colitis, diarrhea, nephritis, myocarditis, infusion related reactions;
- grade 4: myositis/polymyositis, rash, other immune-mediated adverse reaction not previously listed;
- myositis/polymyositis that does not resolve to grade 1 or less within 30 days or if there are signs of respiratory insufficiency.^{2,4}

For further information on management of immune-mediated adverse reactions, see BC Cancer Protocol SCIMMUNE [Management of Immune-Mediated Adverse Reactions to Checkpoint Inhibitors Immunotherapy](#).

Infusion related reactions are reported in up to 2% of patients, including rare cases of severe reactions (i.e., grade 3 or 4). Reactions may manifest as flushing, rash, itching, dizziness, chills, fever, angioedema, breathing difficulties, or back or neck pain. For grade 1 or 2 reactions, decrease the durvalumab infusion rate by 50% or temporarily interrupt the infusion until the reaction has resolved. Consider premedication for subsequent infusions. For management of hypersensitivity reactions, see BC Cancer Protocol SCDRUGRX [Management of Hypersensitivity Reactions to Chemotherapeutic Agents](#). Permanently discontinue durvalumab for grade 3 or 4 reactions.^{2,10}

Upper respiratory tract **infection**, pneumonia, and urinary tract infection are the most commonly reported infections with durvalumab treatment. However, severe infections such as sepsis are sometimes reported. Withhold durvalumab for severe infections.²

INTERACTIONS: none known^{2,3}

SUPPLY AND STORAGE:

Injection: AstraZeneca Canada Inc. supplies durvalumab as 120 mg and 500 mg ready-to-use, single-use (preservative free) vials in a concentration of 50 mg/mL. Refrigerate. Protect from light. Do not shake.²

For basic information on the current brand used at BC Cancer, see [Chemotherapy Preparation and Stability Chart in Appendix](#).

SOLUTION PREPARATION AND COMPATIBILITY:

For basic information on the current brand used at BC Cancer, see [Chemotherapy Preparation and Stability Chart in Appendix](#).

Compatibility: consult detailed reference

PARENTERAL ADMINISTRATION:

BC Cancer administration guideline noted in **bold, italics**

Subcutaneous	no information found
Intramuscular	no information found
Direct intravenous	no information found
<i>Intermittent infusion</i>	<i>over 60 minutes</i> ; administer using an 0.2 or 0.22 micron in-line filter ¹¹⁻¹³
Continuous infusion	no information found
Intraperitoneal	no information found
Intrapleural	no information found
Intrathecal	no information found
Intra-arterial	no information found
Intravesical	no information found

DOSAGE GUIDELINES:

Refer to protocol by which patient is being treated.

Adults:

BC Cancer usual dose noted in ***bold, italics***

<i>Intravenous:</i>	Cycle Length:	
	<i>2 weeks</i> ^{11,12} :	<i>10 mg/kg IV for one dose on day 1</i> (total dose per cycle 10 mg/kg)
	<i>2 weeks</i> ^{12,14} :	<i>750 mg IV for one dose on day 1</i> (total dose per cycle 750 mg)
	<i>3-4 weeks</i> ^{11,13,15} :	<i>20 mg/kg IV for one dose on day 1</i> (total dose per cycle 20 mg/kg)
	<i>3-4 weeks</i> ^{11,13-15} :	<i>1500 mg IV for one dose on day 1</i> (total dose per cycle 1500 mg)

Dose escalation or reduction is not recommended. Temporarily withhold or permanently discontinue treatment if necessary for tolerability and/or patient safety.²

Concurrent radiation: investigational¹⁶

Dosage in renal failure: CrCl ≥30 mL/min: no adjustment required²
CrCl <30 mL/min: no information found

calculated creatinine clearance = $\frac{N * (140 - \text{Age}) \times \text{weight in kg}}{\text{serum creatinine in micromol/L}}$

* For males N=1.23; for females N=1.04

Dosage in hepatic failure: mild impairment (bilirubin ≤ 1.5 x ULN and any AST): no adjustment required²
moderate to severe impairment (bilirubin > 1.5 x ULN and any AST): no information found

Dosage in dialysis: no information found

Children: safety and efficacy not established²

REFERENCES:

1. Massard C, Gordon MS, Sharma S, et al. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. *J Clin Oncol* 2016;34(26):3119-3125.
2. AstraZeneca Canada Inc. IMFINZI® product monograph. Mississauga, Ontario; 4 July 2019.
3. Lexi-Drugs Lexicomp Online(database on the Internet). Durvalumab. Wolters Kluwer Clinical Drug Information Inc., 21 August 2019. Available at: <http://online.lexi.com>. Accessed 22 August 2019.
4. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Management of Immune Checkpoint Inhibitor-Related Toxicities version 2.2019. National Comprehensive Cancer Network, Inc., 8 April 2019. Available at: <http://www.nccn.org>. Accessed 10 September 2019.
5. Angela Chan MD. BC Cancer Agency Lung Tumour Group. Personal communication. 13 September 2019.
6. Alysha Bharmal Pharmacist. BC Cancer Agency Lung Tumour Group. Personal communication. 17 September 2019.
7. BC Cancer. (SCNAUSEA) Guidelines for Prevention and Treatment of Chemotherapy-induced Nausea and Vomiting in Adults. Vancouver, British Columbia: BC Cancer; 1 Dec 2018.

8. BC Cancer Provincial Systemic Therapy Program. Provincial Systemic Therapy Program Policy III-20: Prevention and Management of Extravasation of Chemotherapy. Vancouver, British Columbia: BC Cancer; January 2016.
9. AstraZeneca Canada Inc. IMFINZI® product monograph. Mississauga, Ontario; 23 August 2019.
10. AHFS Drug Information® (database on the Internet). Durvalumab. Wolters Kluwer Clinical Drug Information Inc., 22 February 2019. Available at: <http://online.lexi.com>. Accessed 22 August 2019.
11. AstraZeneca Canada Inc. IMFINZI® product monograph. Mississauga, Ontario; 21 September 2020.
12. BC Cancer Lung Tumour Group. (ULULADUR) BC Cancer Protocol Summary for Treatment of Locally Advanced Non-Small Cell Lung Cancer Using Durvalumab. Vancouver, British Columbia: BC Cancer; 1 January 2021.
13. BC Cancer Lung Tumour Group. (ULULADUR4) BC Cancer Protocol Summary for Treatment of Locally Advanced Non-Small Cell Lung Cancer Using 4-Weekly Durvalumab. Vancouver, British Columbia: BC Cancer; 1 April 2020.
14. Baverel PG, Dubois VFS, Jin CY, et al. Population pharmacokinetics of durvalumab in cancer patients and association with longitudinal biomarkers of disease status. *Clin Pharmacol Ther* 2018;103(4):631-642.
15. Ogasawara K, Newhall K, Maxwell SE, et al. Population pharmacokinetics of an anti-PD-L1 antibody, durvalumab in patients with hematologic malignancies. *Clin Pharmacokinet* 2020;59(2):217-227.
16. Levy A, Massard C, Soria J, et al. Concurrent irradiation with the anti-programmed cell death ligand-1 immune checkpoint blocker durvalumab: Single centre subset analysis from a phase 1/2 trial. *Eur J Cancer* 2016;68:156-162.